The case for capillary rarefaction in the AKI to CKD progression: insights from multiple injury models.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Extracellular vesicles mediate immune regulation in acute kidney injury.Frontiers in immunology · 2026
   Review
2. Hypothermic Perfusion Modifies the Association Between Anti-LG3 Antibodies and Delayed Graft Function in Kidney Recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2023
   Article
3. Intravital Multiphoton Microscopy as a Tool for Studying Renal Physiology, Pathophysiology and Therapeutics.Frontiers in physiology · 2022
   Review
4. Opioid Preconditioning Modulates Repair Responses to Prevent Renal Ischemia-Reperfusion Injury.Pharmaceuticals (Basel, Switzerland) · 2020
   Article

Corrections and comments

• Comment on
  Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.2019

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as